 |
 |
PharmaVOICE - October 2008 Virtual Pharma: Cheaper and Faster, but Doable? By Robin Robinson More and more science-based projects are being shared across silos, networks, and organizations. At the same time, biomedical knowledge is expanding rapidly, but the existing drug-discovery process is unable to keep pace. The industry needs to fix what is broken, and the solution, our experts say, is in the evolution of a virtual business model. Sidebar: GenoMed’s Virtual Pharma Business Model Thought Leaders Stan Bernard, M.D., MBA. President, Bernard Associates, Far Hills, N.J.; Bernard Associates is a pharmaceutical industry management consulting firm offering strategic planning, competitive planning, competitive simulations, and marketing services. For more information, visit bernardassociatesllc.com. Mickey Garcia. Director, Life Sciences Industry Strategy, Dassault Systèmes Enovia, Woodland Hills, Calif.; Dassault Systèmes develops and markets PLM application software and services that support industrial processes and provide a 3D vision of the entire life cycle of products from conception to maintenance; Enovia, which supports global collaborative life-cycle management, is part of its portfolio. For more information, visit 3ds.com. David W. Moskowitz, M.D., FACP. Founder, Chairman, CEO, and Chief Medical Officer, GenoMed, St. Louis; GenoMed is a medical genomics company that uses knowledge of disease-causing genes to improve patient outcomes and pursues massively parallel drug development through creation of a virtual pharmaceutical consortium, including its own virtual pharmaceutical company, GenoDrugDiscovery. For more information, visit genomed.com. Bernard Munos. Advisor, Corporate Strategy, Eli Lilly and Company, Indianapolis; Eli Lilly is an innovation-driven corporation, developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. For more information, visit lilly.com. Jeff Shrager, Ph.D. Chief Technology Officer, CollabRx, Palo Alto, Calif.; CollabRx builds and operates virtual biotechnology companies for foundations and patients who urgently seek cures for their diseases. For more information, visit collabrx.com.
|
